Immunic (IMUX) Accounts Payables (2013 - 2026)

Immunic has disclosed Accounts Payables across 14 years of filings, most recently posting $11.0 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $11.0 million, up 83.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.0 million (up 83.18% YoY), and the FY2025 annual result was $10.1 million, up 29.21% from the prior year.
• Accounts Payables came in at $11.0 million for Q1 2026 at Immunic, up from $10.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $11.0 million in Q1 2026 to a low of $3.2 million in Q3 2023.
• The 5-year median for Accounts Payables is $6.0 million (2025), against an average of $6.2 million.
• Across the five-year window, Accounts Payables tumbled 67.28% in 2022 and surged 88.87% in 2024, its largest moves.
• Immunic's Accounts Payables stood at $4.3 million in 2022, then climbed by 19.11% to $5.1 million in 2023, then jumped by 53.87% to $7.8 million in 2024, then increased by 29.21% to $10.1 million in 2025, then gained by 8.61% to $11.0 million in 2026.
• The last three Accounts Payables figures came in at $11.0 million (Q1 2026), $10.1 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.